Specifically, it compares peripheral BDNF levels among ultra-high-risk individuals, healthy controls, and patients with first-episode psychosis or chronic schizophrenia, to assess whether alterations are already detectable during the early or prodromal phase. The gene discussed is BDNF; the disease is psychotic disorder.